- $1.46bn
- $1.28bn
- $2.80m
Absci Corp expected to post a loss of 22 cents a share - Earnings Preview
Brief: Absci Q4 Basic EPS USD -0.25
U.S. RESEARCH ROUNDUP-Ashland, Oportun Financial, Palomar Holdings
U.S. STOCKS ON THE MOVE-Shift4 Payments, Chart Industries, Applied Therapeutics
U.S. STOCKS ON THE MOVE-Permian Resources, Vivani, Incannex
Biotech firm Absci dips on stock offering
Brief: Absci Prices Public Offering Of Common Stock At $4.50 Per Share
Brief: Absci Announces Proposed Public Offering Of Common Stock
Brief: Absci Initiates IND-Enabling Studies for ABS-101
Brief: Absci Appoints Professor Sir Mene Pangalos To Its Board Of Directors
Brief: Absci Corp Expects To Initiate Investigational New Drug Application Enabling Studies For Abs-101 In Feb 2024
Brief: Absci And Precisionlife Announce Strategic Research And Development Partnership To Jointly Develop Ai-Enabled Drug Pipeline
Brief: Absci Corp Says Size Of Board Will Be Fixed At Seven Directors
U.S. STOCKS ON THE MOVE-Korro Bio, Arrowhead Pharma, Structure Therapeutics
U.S. STOCKS ON THE MOVE-Nuvei, SilverSun Technologies, RedHill Biopharma
U.S. STOCKS ON THE MOVE-ONEOK, Jabil, Spotify
U.S. STOCKS ON THE MOVE-Spotify, Uber, Carvana
Absci up on cancer drug deal with AstraZeneca
UK Stocks-Factors to watch on Dec 4 (updated)